Cantuzumab
Jump to navigation
Jump to search
Cantuzumab is a monoclonal antibody designed for the treatment of cancers. Also known as huC242 it binds the CanAg antigen.[1]
It is typically linked to one of several cytotoxic agents, yielding antibody-drug conjugates :
huC242 targets CanAg
"HuC242 binds to the extracellular domain of the tumor-associated carbohydrate antigen known as CanAg (a novel glycoform of MUC1). CanAg is strongly expressed in most pancreatic, biliary, and colorectal cancers. It is also expressed in a substantial proportion of gastric cancers (55%), uterine cancers (45%), non-small cell lung cancers (40%), and bladder cancers (40%)."[2]
References
- ^ Rodon, J; Garrison, M; Hammond, LA; de Bono, J; Smith, L; Forero, L; Hao, D; Takimoto, C; Lambert, JM; Pandite, L; Howard, M; Xie, H; Tolcher, AW (2008). "Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study". Cancer Chemother Pharmacol. 62 (5): 911–9. doi:10.1007/s00280-007-0672-8. PMID 18301896. S2CID 5829870.
- ^ A Phase I Study of Cantuzumab Mertansine Administered as a Single Intravenous Infusion Once Weekly in Patients with Advanced Solid Tumors. Helft et al. 2004
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |